Free Trial
NASDAQ:RNXT

RenovoRx Q2 2023 Earnings Report

RenovoRx logo
$1.04 +0.01 (+0.97%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RenovoRx EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

RenovoRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RenovoRx Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 17, 2023
Conference Call Time
8:30AM ET

Upcoming Earnings

RenovoRx's Q1 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

RenovoRx Earnings Headlines

RenovoRx (RNXT) Projected to Post Earnings on Friday
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More RenovoRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RenovoRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RenovoRx and other key companies, straight to your email.

About RenovoRx

RenovoRx (NASDAQ:RNXT), a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

View RenovoRx Profile

More Earnings Resources from MarketBeat